A citation-based method for searching scientific literature

Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H Sayre, James McNamara, Jeffrey A Bluestone. Diabetes 2013
Times Cited: 186







List of co-cited articles
969 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Mark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Paula F McGee, Antoinette M Moran,[...]. N Engl J Med 2009
632
49

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
347
43

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Mark R Rigby, Kristina M Harris, Ashley Pinckney, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Kurt J Griffin, Eva Tsalikian,[...]. J Clin Invest 2015
139
40

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin,[...]. N Engl J Med 2002
839
39

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,[...]. N Engl J Med 2005
787
35

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin,[...]. Lancet 2011
290
33

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
William Hagopian, Robert J Ferry, Nicole Sherry, David Carlin, Ezio Bonvini, Syd Johnson, Kathryn E Stein, Scott Koenig, Anastasia G Daifotis, Kevan C Herold,[...]. Diabetes 2013
116
30

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley,[...]. N Engl J Med 2019
197
29

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Richard A Insel, Jessica L Dunne, Mark A Atkinson, Jane L Chiang, Dana Dabelea, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jeffrey P Krischer, Åke Lernmark,[...]. Diabetes Care 2015
340
28

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
S Alice Long, Jerill Thorpe, Hannah A DeBerg, Vivian Gersuk, James Eddy, Kristina M Harris, Mario Ehlers, Kevan C Herold, Gerald T Nepom, Peter S Linsley. Sci Immunol 2016
76
35

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A Dimeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Diabetes Care 2014
110
24

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Ronnie Aronson, Peter A Gottlieb, Jens S Christiansen, Thomas W Donner, Emanuele Bosi, Bruce W Bode, Paolo Pozzilli. Diabetes Care 2014
68
32

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A Bluestone, Jane H Buckner, Mark Fitch, Stephen E Gitelman, Shipra Gupta, Marc K Hellerstein, Kevan C Herold, Angela Lares, Michael R Lee, Kelvin Li,[...]. Sci Transl Med 2015
486
22

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Michael J Haller, Stephen E Gitelman, Peter A Gottlieb, Aaron W Michels, Stephen M Rosenthal, Jonathan J Shuster, Baiming Zou, Todd M Brusko, Maigan A Hulme, Clive H Wasserfall,[...]. J Clin Invest 2015
94
22

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Kevan C Herold, Stephen E Gitelman, Umesh Masharani, William Hagopian, Brygida Bisikirska, David Donaldson, Kristina Rother, Beverly Diamond, David M Harlan, Jeffrey A Bluestone. Diabetes 2005
459
21

B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Mark D Pescovitz, Carla J Greenbaum, Brian Bundy, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Antoinette Moran, Philip Raskin,[...]. Diabetes Care 2014
117
21

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Mark R Rigby, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Chetanbabu M Patel, Kurt J Griffin, Eva Tsalikian, Peter A Gottlieb,[...]. Lancet Diabetes Endocrinol 2013
107
19

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Carla J Greenbaum, Craig A Beam, David Boulware, Stephen E Gitelman, Peter A Gottlieb, Kevan C Herold, John M Lachin, Paula McGee, Jerry P Palmer, Mark D Pescovitz,[...]. Diabetes 2012
193
19


Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Antoinette Moran, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Philip Raskin,[...]. Lancet 2013
210
18

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.
Anette G Ziegler, Marian Rewers, Olli Simell, Tuula Simell, Johanna Lempainen, Andrea Steck, Christiane Winkler, Jorma Ilonen, Riitta Veijola, Mikael Knip,[...]. JAMA 2013
529
18

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
Jeffrey P Krischer, Desmond A Schatz, Brian Bundy, Jay S Skyler, Carla J Greenbaum. JAMA 2017
66
27

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.
Michael J Haller, Desmond A Schatz, Jay S Skyler, Jeffrey P Krischer, Brian N Bundy, Jessica L Miller, Mark A Atkinson, Dorothy J Becker, David Baidal, Linda A DiMeglio,[...]. Diabetes Care 2018
40
45

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Diane K Wherrett, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks,[...]. Lancet 2011
226
17

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
James E Tooley, Nalini Vudattu, Jinmyung Choi, Chris Cotsapas, Lesley Devine, Khadir Raddassi, Mario R Ehlers, James G McNamara, Kristina M Harris, Sai Kanaparthi,[...]. Eur J Immunol 2016
36
47

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
Michael J Haller, S Alice Long, J Lori Blanchfield, Desmond A Schatz, Jay S Skyler, Jeffrey P Krischer, Brian N Bundy, Susan M Geyer, Megan V Warnock, Jessica L Miller,[...]. Diabetes 2019
31
54

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
S Alice Long, Mary Rieck, Srinath Sanda, Jennifer B Bollyky, Peter L Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2012
210
16

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
B Keymeulen, M Walter, C Mathieu, L Kaufman, F Gorus, R Hilbrands, E Vandemeulebroucke, U Van de Velde, L Crenier, C De Block,[...]. Diabetologia 2010
211
16

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Jay S Skyler, Jeffrey P Krischer, Joseph Wolfsdorf, Catherine Cowie, Jerry P Palmer, Carla Greenbaum, David Cuthbertson, Lisa E Rafkin-Mervis, H Peter Chase, Ellen Leschek. Diabetes Care 2005
386
16

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Stephen E Gitelman, Peter A Gottlieb, Eric I Felner, Steven M Willi, Lynda K Fisher, Antoinette Moran, Michael Gottschalk, Wayne V Moore, Ashley Pinckney, Lynette Keyes-Elstein,[...]. Diabetologia 2016
42
38

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
K C Herold, S E Gitelman, S M Willi, P A Gottlieb, F Waldron-Lynch, L Devine, J Sherr, S M Rosenthal, S Adi, M Y Jalaludin,[...]. Diabetologia 2013
69
21

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Lucy Mastrandrea, Jihnhee Yu, Torsten Behrens, John Buchlis, Christine Albini, Shannon Fourtner, Teresa Quattrin. Diabetes Care 2009
145
14

Genetics, pathogenesis and clinical interventions in type 1 diabetes.
Jeffrey A Bluestone, Kevan Herold, George Eisenbarth. Nature 2010
668
14

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
Kirsti Näntö-Salonen, Antti Kupila, Satu Simell, Heli Siljander, Tiina Salonsaari, Anne Hekkala, Sari Korhonen, Risto Erkkola, Jukka I Sipilä, Lotta Haavisto,[...]. Lancet 2008
242
14

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Johnny Ludvigsson, David Krisky, Rosaura Casas, Tadej Battelino, Luis Castaño, James Greening, Olga Kordonouri, Timo Otonkoski, Paolo Pozzilli, Jean-Jacques Robert,[...]. N Engl J Med 2012
189
14

Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline.
Tihamer Orban, Craig A Beam, Ping Xu, Keith Moore, Qi Jiang, Jun Deng, Sarah Muller, Peter Gottlieb, Lisa Spain, Mark Peakman. Diabetes 2014
53
24

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Stephen E Gitelman, Peter A Gottlieb, Mark R Rigby, Eric I Felner, Steven M Willi, Lynda K Fisher, Antoinette Moran, Michael Gottschalk, Wayne V Moore, Ashley Pinckney,[...]. Lancet Diabetes Endocrinol 2013
84
15


Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
13

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
L Chatenoud, E Thervet, J Primo, J F Bach. Proc Natl Acad Sci U S A 1994
499
13

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
S Alice Long, Jerill Thorpe, Kevan C Herold, Mario Ehlers, Srinath Sanda, Noha Lim, Peter S Linsley, Gerald T Nepom, Kristina M Harris. Cell Immunol 2017
28
46

Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.
Ken T Coppieters, Francesco Dotta, Natalie Amirian, Peter D Campbell, Thomas W H Kay, Mark A Atkinson, Bart O Roep, Matthias G von Herrath. J Exp Med 2012
402
12


Control of TH17 cells occurs in the small intestine.
Enric Esplugues, Samuel Huber, Nicola Gagliani, Anja E Hauser, Terrence Town, Yisong Y Wan, William O'Connor, Anthony Rongvaux, Nico Van Rooijen, Ann M Haberman,[...]. Nature 2011
426
12

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.
Peter A Gottlieb, Scott Quinlan, Heidi Krause-Steinrauf, Carla J Greenbaum, Darrell M Wilson, Henry Rodriguez, Desmond A Schatz, Antoinette M Moran, John M Lachin, Jay S Skyler. Diabetes Care 2010
94
12

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.
Diane K Wherrett, Jane L Chiang, Alan M Delamater, Linda A DiMeglio, Stephen E Gitelman, Peter A Gottlieb, Kevan C Herold, Daniel J Lovell, Trevor J Orchard, Christopher M Ryan,[...]. Diabetes Care 2015
48
25

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Kevan C Herold, Stephen Gitelman, Carla Greenbaum, Jennifer Puck, William Hagopian, Peter Gottlieb, Peter Sayre, Peter Bianchine, Emelita Wong, Vicki Seyfert-Margolis,[...]. Clin Immunol 2009
133
11

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.
Mériam Belghith, Jeffrey A Bluestone, Samia Barriot, Jérôme Mégret, Jean-François Bach, Lucienne Chatenoud. Nat Med 2003
479
11

Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.
Hillary A Keenan, Jennifer K Sun, Jared Levine, Alessandro Doria, Lloyd P Aiello, George Eisenbarth, Susan Bonner-Weir, George L King. Diabetes 2010
321
11

β cell death and dysfunction during type 1 diabetes development in at-risk individuals.
Kevan C Herold, Sahar Usmani-Brown, Tara Ghazi, Jasmin Lebastchi, Craig A Beam, Melena D Bellin, Michel Ledizet, Jay M Sosenko, Jeffrey P Krischer, Jerry P Palmer. J Clin Invest 2015
99
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.